Study of Pemetrexed Versus Pemetrexed Plus Erlotinib as Treatment of Nonsquamous Non-Small Cell Lung Cancer (NSCLC)
Launched by ELI LILLY AND COMPANY · Mar 9, 2007
Trial Information
Current as of July 05, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Histological or cytological diagnosis of locally advanced or metastatic NSCLC that is of nonsquamous histology and not amenable to curative therapy.
- • Failure of previous treatment with one prior platinum-based chemotherapy regimen.
- • Good performance status.
- • Adequate bone marrow reserve, renal and hepatic functions.
- Exclusion Criteria:
- • Serious concomitant systemic disease.
- • Inability to take oral medication.
- • Inability or unwillingness to take vitamin supplementation and corticosteroids.
- • Pregnancy / Breast-feeding.
- • Treatment with certain medicines that prevent blood from clotting.
About Eli Lilly And Company
Eli Lilly and Company is a global healthcare leader dedicated to creating innovative medicines that improve patient outcomes across a range of therapeutic areas, including diabetes, oncology, immunology, and neurodegenerative diseases. With a rich history of scientific research and a commitment to advancing healthcare, Lilly invests significantly in clinical trials to develop new treatments and enhance existing therapies. The company prioritizes patient safety and ethical standards in its clinical research, fostering collaboration with healthcare professionals and stakeholders to ensure the delivery of high-quality, evidence-based solutions that address unmet medical needs worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ulm, , Germany
Valencia, , Spain
Nyiregyhaza, , Hungary
Szekesfehervar, , Hungary
Linkoping, , Sweden
Barcelona, , Spain
Freiburg, , Germany
Tübingen, , Germany
Hannover, , Germany
Lund, , Sweden
Solna, , Sweden
Deszk, , Hungary
Alicante, , Spain
Salzburg, , Austria
Vienna, , Austria
Bochum, , Germany
Gauting, , Germany
Gerlingen, , Germany
Hamburg, , Germany
Immenhausen, , Germany
Trier, , Germany
Matrahaza, , Hungary
Madrid, , Spain
Patients applied
Trial Officials
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director
Eli Lilly and Company
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials